Infectious clone of human parvovirus B19 and methods

Details Infectious clone of human parvovirus B19 and methods Infectious clone of human parvovirus B19 and methods

2004-07-09

2009-10-06

Lucas, Zachariah (Department: 1648)

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

C435S239000, C435S320100, C435S325000, C536S023720

Reexamination Certificate

active

07598071

ABSTRACT:
The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are useful for producing infectious virus. Infectious virus is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B19 infections.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 6632670 (2003-10-01), Wadsworth et al.
patent: 6669935 (2003-12-01), Oldfield et al.
patent: 6677155 (2004-01-01), Sena-Esteves et al.
patent: 6743772 (2004-06-01), Broliden et al.
patent: 2004/0014220 (2004-01-01), Siebenkotten et al.
Morita et al., “Human parvovirus B19 induces cell cycle arrest at G(2) phase with accumulation of mitotic cyclins,” Journal of Virology, vol. 75 No. 16, pp. 7555-7563 (Aug. 2001).
Samulski et al., “A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication,” Journal of Virology, vol. 61 No. 10, pp. 3096-3101 (Oct. 1987).
Zhi et al., “Construction and sequencing of an infectious clone of the human parvovirus B19,” Virology, vol. 318 No. 1, pp. 142-152 (Jan. 2004).
GenBank M29711 “Parvovirus B19 inverted terminal repeat, 3′ end,” (Aug. 1993).
GenBank M29710, “Parvovirus B19 inverted terminal repeat, 5′ end” (Aug. 1993).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, vol. 247, No. 4948. (Mar. 16, 1990), pp. 1306-1310.
Filippone et al., “VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones ,” Virology, vol. 374 No. 2, pp. 444-452 (May 2008).
GenBank Accession No. AY386330 dated Nov. 12, 2004.
GenBank Accession No. M13178 dated May 17, 1995.
GenBank Accession No. AF162273 dated Aug. 2, 1999.
GenBank Accession No. M24682 dated Aug. 3, 1993.
Berns, K., “Parvoviridae and Their Replication”,Virology, Second Edition. Fields et al. Raven.Press Ltd, NY, pp. 1743-1763 (1990).
Brodeur et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas”,Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, pp. 51-63 (1987).
Brown et al., “Molecular, cellular and clinical aspects of Parvovirus B19 infection”,Crit. Rev.Oncol./Hematol., 16:1-31 (1994).
Brown et al., “In vitro propagation of parvovirus B19 in primary foetal liver culture”,J. Gen. Vir., 72(3):741-745 (1991).
Brown et al., “Erythrocyte P antigen: cellular receptor for B19 parvovirus”,Science, 262:114-117 (1993).
Liu et al., “A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus”,Journal of Virology, 66(8):4686-4692 (1992).
Lutz-Freyermuth et al., “Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of U1 RNA”,Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990).
Martin et al., “GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinie Atrial K+Channel Currents”,Science, 255:192-194 (1992).
Miyagawa et al., “Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity”,J. Virol. Methods, 83:45-54 (1999).
Mori et al ., “Structure and mapping of the DNA of human parvovirus B19”,J. Gen. Virol, 68: 2797-2806 (1987).
Munshi et al., “Successful Replication of Parvovirus B19 in the Human Megakaryocytic Leukemia Cell Line MB-02”,Journal of Virology, 67(1):562-566 (1993).
Ozawa et al., “Replication of the B19 Parvovirus in Human Bone Marrow Cell Cultures”,Science, 233:883-886 (1986).
Paborsky e tal., “Mammalian cell transient expression of tissue factor for the production of antigen”,Protein Engineering, 3(6):547-553 (1990).
Ponnazhagen et al., “Recombinant Human Parvovirus B19 Vectors: Erythroid Cell-Specific Delivery and Expression of Transduced Genes”,Journal of Virology, 72(6):5224-5230 (1998).
Presta, “Antibody Engineering”,Curr. Op. Struct. Biol., 2:593-596 (1992).
Riechmann et al., “Reshaping human antibodies for therapy”,Nature, 332:323-329 (1988).
Shade et al., “Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis”,J. Virol., 58:921-936 (1986).
Shimomura et al., “First continuous propagation of B19 parvovirus in a cell line”,Blood, 79:18-24 (1992).
Skinner et al., “Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and MutantrasGTPase-activating Proteins*”,J. Biol. Chem., 266(22):14163-14166 (1991).
Srivastava et al., “Construction of a recombinant human parvovirus B19: Adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus”,Proc. Natl. Acad. Sci. USA, 86:8078-8082 (1989).
St. Amand et al., “A Novel Protein Encoded by Small RNAs of Parovirus B19”,Virology, 195(2):448-455 (1993).
St. Amand et al., “Identification and Characterization of a Family of 11-kDa Proteins Encoded by the Human Parvovirus B19”,Virology, 192:121-131 (1993).
Summers et al., “Characterization of the genome of the agent of erythrocyte asplasia permits its classification as a human parvovirus”,J. Gen. Virology, 64:2527-2532 (1983).
Vaswani et al., “Humanized antibodies as potential therapeutic drugs”,Ann. Allergy, Asthma&Immunol.81(2):105-115 (1998).
Yaegashi et al., “Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from liver”,J. Virology, 63(6):2422-2426 (1989).
Yoshimoto et al., “A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response”,J. Virology, 65(12):7056-7060 (1991).
Zhi et al., “Construction and sequencing of an infectious clone of the human parvovirus B19”,22nd Annual Meeting American Society for Virology, available online Apr. 13, 2003.
Zhi et al., “Construction and sequencing of an infectious clone of the human parvovirus B19”,Virology, 318:142-152 (2004) published online Dec. 3, 2003.
Brown et al., “Resistance to Parvovirus B19 Infection Due to Lack of Virus Receptor”,N. Engl. J. Med., 330:1192-1196 (1994).
Cotmore et al., “Characterization and molecular cloning of a human parvovirus genome”,Science, 226:1161-1165 (1986).
Deiss et al., “Cloning of the Human Parvovirus B19 Genome and Structural Analysis of Its Palindromic Termini”,Virology, 175(1):247-254 (1990).
Dorsch et al., “VP1 Unique Region of Parvovirus B19 and Its Constituent Phospholipase A2-Like Activity”,Journal of Virology, 76(4):2014-2018 (2002).
Erdman et al., “Genetic diversity of human parvovirus B19: sequence analysis of the VP1/VP2 gene from multiple isolates”,J. Gen. Virol., 77(11):2767-2774 (1996).
Evan et al., “Isolation of Monoclonal Antibodies Specific for Human c-mycProto-Oncogene Product”,Molecular and Cellular Biology, 5(12):3610-3616 (1985).
Fan et al., “The Small 11-kDa Protein from B19 Parvovirus Binds Growth Factor Receptor-Binding Protein 2In Vitroin a Src Homology 3 Domain/Ligand-Dependent manner”,Virology, 291:285-291 (2001).
Field et al., “Purification of aRAS-Responsive Adenylyl Cyclase Complex fromSaccharomyces cerevisiaeby Use of an Epitope Addition Method”,Mol. Cell. Biol., 8(5):2159-2165 (1988).
Goding, “Production of Monoclonal Antibodies”,M

Affiliated with

Also associated with

Rating

Infectious clone of human parvovirus B19 and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Infectious clone of human parvovirus B19 and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Infectious clone of human parvovirus B19 and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4094209